Clinical Trial Update: Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for enfortumab vedotin in urothelial carcinoma describes schedule de-escalation in metastatic/locally advanced disease. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING